[go: up one dir, main page]

MX2013010530A - Combinacion de oligonucleotido anti-clusterina con antagonistas del receptor de androgeno para el tratamiento de cancer de prostata. - Google Patents

Combinacion de oligonucleotido anti-clusterina con antagonistas del receptor de androgeno para el tratamiento de cancer de prostata.

Info

Publication number
MX2013010530A
MX2013010530A MX2013010530A MX2013010530A MX2013010530A MX 2013010530 A MX2013010530 A MX 2013010530A MX 2013010530 A MX2013010530 A MX 2013010530A MX 2013010530 A MX2013010530 A MX 2013010530A MX 2013010530 A MX2013010530 A MX 2013010530A
Authority
MX
Mexico
Prior art keywords
combination
prostate cancer
receptor antagonist
androgen receptor
treatment
Prior art date
Application number
MX2013010530A
Other languages
English (en)
Inventor
Martin Gleave
Amina Zoubeidi
Original Assignee
Univ British Columbia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ British Columbia filed Critical Univ British Columbia
Publication of MX2013010530A publication Critical patent/MX2013010530A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/14—Ectoparasiticides, e.g. scabicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se describe un método para tratar un sujeto mamífero que padece de cáncer de próstata que comprende i) un oligonucleótido que reduce la expresión de clusterina y ii) un antagonista del receptor de andrógeno que tiene la estructura (Ver Formula) o una sal farmacéuticamente aceptable del mismo, cada uno en una cantidad que cuando en combinación con el otro es efectivo para tratar el sujeto mamífero.
MX2013010530A 2011-03-14 2012-03-14 Combinacion de oligonucleotido anti-clusterina con antagonistas del receptor de androgeno para el tratamiento de cancer de prostata. MX2013010530A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161452583P 2011-03-14 2011-03-14
US201161453309P 2011-03-16 2011-03-16
US201161453885P 2011-03-17 2011-03-17
US201161493336P 2011-06-03 2011-06-03
PCT/IB2012/000609 WO2012123820A1 (en) 2011-03-14 2012-03-14 Combination of anti-clusterin oligonucleotide with androgen receptor antagonist for the treatment of prostate cancer

Publications (1)

Publication Number Publication Date
MX2013010530A true MX2013010530A (es) 2014-05-01

Family

ID=46830100

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013010530A MX2013010530A (es) 2011-03-14 2012-03-14 Combinacion de oligonucleotido anti-clusterina con antagonistas del receptor de androgeno para el tratamiento de cancer de prostata.

Country Status (12)

Country Link
US (1) US20140088178A1 (es)
EP (1) EP2685989A4 (es)
JP (1) JP2014509607A (es)
KR (1) KR20140048106A (es)
AU (1) AU2012228007B2 (es)
CA (1) CA2830191A1 (es)
IL (1) IL227718A0 (es)
MX (1) MX2013010530A (es)
RU (1) RU2013145551A (es)
SG (1) SG192952A1 (es)
WO (1) WO2012123820A1 (es)
ZA (1) ZA201307558B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ513757A (en) 1999-02-26 2004-12-24 Univ British Columbia Antisense oligonucleotides to inhibit TRPM-2 expression and delay androgen independance in prostatic tumour cells
US7569551B2 (en) 2000-02-25 2009-08-04 The University Of British Columbia Chemo- and radiation-sensitization of cancer by antisense TRPM-2 oligodeoxynucleotides
KR20140038388A (ko) 2011-03-15 2014-03-28 더 유니버시티 오브 브리티쉬 콜롬비아 전립선암의 치료를 위한 항-클러스테린 올리고뉴클레오타이드와 hsp90 저해제의 병용
CN106442992A (zh) * 2016-08-03 2017-02-22 上海延安药业有限公司 阿比特龙衍生物的药代动力学评估方法
WO2019222272A1 (en) 2018-05-14 2019-11-21 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
CA3138197A1 (en) 2019-05-14 2020-11-19 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
CN114072860A (zh) 2019-07-25 2022-02-18 菲利普莫里斯生产公司 用于气溶胶生成制品的自动售货设备
EP4058464A1 (en) 2019-11-13 2022-09-21 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
CA3214408A1 (en) 2021-03-23 2022-09-29 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
IL308104A (en) 2021-05-03 2023-12-01 Nuvation Bio Inc Nuclear hormone receptor-targeted compounds against cancer

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8710020B2 (en) * 2004-04-02 2014-04-29 The University Of British Columbia Clusterin antisense therapy for treatment of cancer
US8524755B2 (en) * 2009-02-24 2013-09-03 Medivation Prostate Therapeutics, Inc. Specific diarylhydantoin and diarylthiohydantoin compounds

Also Published As

Publication number Publication date
AU2012228007B2 (en) 2016-09-08
IL227718A0 (en) 2013-09-30
EP2685989A4 (en) 2014-12-10
SG192952A1 (en) 2013-09-30
WO2012123820A1 (en) 2012-09-20
US20140088178A1 (en) 2014-03-27
RU2013145551A (ru) 2015-04-20
NZ616465A (en) 2015-08-28
ZA201307558B (en) 2015-08-26
JP2014509607A (ja) 2014-04-21
CA2830191A1 (en) 2012-09-20
EP2685989A1 (en) 2014-01-22
KR20140048106A (ko) 2014-04-23
AU2012228007A1 (en) 2013-10-31

Similar Documents

Publication Publication Date Title
MX2013010530A (es) Combinacion de oligonucleotido anti-clusterina con antagonistas del receptor de androgeno para el tratamiento de cancer de prostata.
MX2020004689A (es) Tratamiento del cancer con inhibidores de tor cinasa.
PH12013502487A1 (en) Sglt-2 inhibitors for treating metabolic disorders in patients treated with neuroleptic agents
PH12017500070A1 (en) Methods of treating cancer using tigit inhibitors and anti-cancer agents
BR112013021318A2 (pt) vetor e método de tratar ou prevenir coroideremia em um paciente com necessidade do mesmo
WO2013056148A3 (en) Scd1 antagonists for treating cancer
PH12014502048B1 (en) Treatment of cancer with tor kinase inhibitors
MX2015013177A (es) Combinacion de tratamientod de cancer usando microarns e inhibidores de egfr-tki.
PH12014502047B1 (en) Treatment of cancer with tor kinase inhibitors
PH12014502046A1 (en) Treatment of cancer with tor kinase inhibitors
MX360774B (es) Antagonistas de progesterona.
PH12014500683A1 (en) Methods and systems for identfying and treating anti-progestin sensitive tumors
PH12015502342A1 (en) Combination therapy comprising a dihydropyrazino-pyrazine compound and an androgen receptor antagonist for treating prostate cancer
SG10201902568YA (en) Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
MX2018010223A (es) Terapia combinada para tratamiento de cancer de ovario.
PH12015500867A1 (en) Treatment of prostate cancer with tor kinase inhibitors
ZA201307560B (en) Combination of anti-clusterin oligonucleotide with hsp90 inhibitor for the treatment of prostate cancer
AU2012346899A8 (en) Materials and methods related to NSAID chemoprevention in colorectal cancer
MX362111B (es) Un metodo para mejorar la funcion hepatica.
WO2011128434A3 (en) Treatment of endocrine resistant breast cancer
WO2013040504A3 (en) Srpx for treatment of cancer
GB2518539A (en) An ICAM-1 anti sense for the treatment of inflammation and pain in a rectal stump